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Background: Aromatase inhibitors are considered standard adjuvant endocrine treatment of postmenopausal
women with hormone receptor-positive breast cancer, but it remains uncertain whether aromatase inhibitors should
be given upfront or sequentially with tamoxifen. Awaiting results from ongoing randomized trials, we examined
prognostic factors of an early relapse among patients in the BIG 1-98 trial to aid in treatment choices.
Patients and methods: Analyses included all 7707 eligible patients treated on BIG 1-98. The median follow-up was
2 years, and the primary end point was breast cancer relapse. Cox proportional hazards regression was used to
identify prognostic factors.
Results: Two hundred and eighty-five patients (3.7%) had an early relapse (3.1% on letrozole, 4.4% on tamoxifen).
Predictive factors for early relapse were node positivity (P < 0.001), absence of both receptors being positive (P <
0.001), high tumor grade (P < 0.001), HER-2 overexpression/amplification (P < 0.001), large tumor size (P = 0.001),
treatment with tamoxifen (P = 0.002), and vascular invasion (P = 0.02). There were no significant interactions between
treatment and the covariates, though letrozole appeared to provide a greater than average reduction in the risk of early
relapse in patients with many involved lymph nodes, large tumors, and vascular invasion present.
Conclusion: Upfront letrozole resulted in significantly fewer early relapses than tamoxifen, even after adjusting for
significant prognostic factors.
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introduction
The primary core analysis of the BIG 1-98 trial, coordinated
by the International Breast Cancer Study Group, compared
letrozole to tamoxifen given for 5 years alone or in sequence,
in postmenopausal women with estrogen and/or progesterone
receptor (ER/PgR)-positive breast cancer. Patients were
randomized from 1998 to 2003 to tamoxifen for 5 years,
letrozole for 5 years, tamoxifen for 2 years followed by letrozole
for 3 years or letrozole for 2 years followed by tamoxifen for
3 years. A significant benefit of letrozole (19% risk reduction)
on disease-free survival was seen, particularly for distant
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A total of five trials have shown that aromatase inhibitors
improve disease-free survival compared with tamoxifen alone.
ATAC (anastrozole) [2] and BIG 1-98 (letrozole) [1] compared
upfront aromatase inhibitor for 5 years to tamoxifen for 5 years.
The other three trials, IES (exemestane) [3], ITA (anastrozole)
[4], and ABCSG 8-ARNO 95 (anastrozole) [5], compared
tamoxifen alone for 5 years to sequential treatment with
tamoxifen for 2–3 years and aromatase inhibitor for 2–3 years.
While waiting for the definitive results of BIG 1-98 comparing
upfront letrozole to sequential treatment, we conducted an
exploratory analysis to determine which patients could benefit
most from the best treatment to prevent early relapse.
The focus of the present analysis was to retrospectively
identify patients who might most benefit from the initial
selection of letrozole versus tamoxifen, on the basis of clinical
and pathological prognostic factors of early relapse.
patients and methods
The analysis population was comprised of eligible patients randomized to
BIG 1-98 and excluded patients who withdrew consent to participate in
the trial before initiating treatment. Patients were included according to
the treatment to which they were randomized.
The primary end point was breast cancer relapse, defined as the first
proven invasive local, contralateral breast, regional, or distant recurrence in
any site. Secondly, nonbreast malignancies were ignored and deaths without
proven recurrence were censored. Analyses were based on treatment with
tamoxifen or letrozole alone; follow-up and events were censored if they
occurred beyond 2 years after randomization for patients in the two
monotherapy arms, and beyond the date of treatment switch or 2 years after
randomization (whichever was earlier) for patients in the sequential
treatment arms. The analysis thus focused exclusively on early relapse.
Prognostic factors tested included age at randomization (<55, 55–64, ‡65
years), pathological tumor size (£2, >2 cm), tumor grade (1, 2, 3, missing),
mitotic grade (1, 2, 3, missing), locally assessed ER/PgR status (ER+/PgR+,
ER+/PgR, ER+/PgR unknown, ER/PgR+), centrally assessed HER-2
status (overexpressed/amplified, normal, missing), axillary node positivity
(zero, one to three, four or more positive nodes), and vascular invasion (yes,
no, not assessable). All covariates were modeled categorically using indicator
variables. Significance for HER-2 status was on the basis of the pairwise
comparison of overexpressed versus normal, and significance for vascular
invasion was on the basis of the pairwise comparison of yes versus no.
Covariates with >5% of values missing were modeled with an indicator for
missing values; covariates with £5% values were not modeled with an
indicator, and patients with missing values for these covariates were
excluded from the models.
Cox proportional hazards regression analyses were used to identify
significant prognostic factors, and all models included randomized
treatment assignment (letrozole, tamoxifen). Only covariates that were
significant ‘univariately’ (in a model that also included treatment) were
considered in multivariate models. A full multivariate model was then fitted,
and a manual backwards selection was conducted. To ensure noncollinearity
in multivariate analyses, Spearman rank correlations were examined and
Akaike’s Information Criterion (AIC) was used to select between covariates
with a correlation >0.50. After the significant main effects were identified,
interactions between the main effects and treatment were tested to
determine whether the effect of the covariate on the risk of relapse differed
according to the treatment the patient initially received; interactions were
tested individually to conserve power.
A significance level of a = 0.05 was applied throughout without
adjustment for multiple comparisons. Verification of the Cox proportional
hazards assumption was done through visual inspection of the
log(log(S(t))) plot, where S(t) is the survivor function.
results
A total of 7707 of the 8028 patients were included (18 patients
withdrew consent to participate before initiating treatment, 133
patients were ineligible, and another 170 had missing covariate
values). At a median follow-up of 2 years (range 0.01–2 years),
285 patients (3.7%) had a relapse. Early relapse rates are 3.0%
for the letrozole group and 4.4% for the tamoxifen group. The
dominant sites of relapse are presented in Table 1 by treatment.
Table 2 gives the breakdown of the covariates by relapse
status and also includes information on treatments received
(radiotherapy, surgery, and chemotherapy). In ‘univariate’
models (including treatment), age was the only nonsignificant
covariate (P = 0.67). Tumor grade and mitotic grade had
a correlation of 0.60 and virtually identical AIC values; since
tumor grade is a more commonly reported characteristic, it was
kept in the full multivariate mode and mitotic grade was
dropped. Node positivity and tumor size had a moderate
correlation of 0.26; all other correlations were <16% in
magnitude.
The significant prognostic factors in a multivariate analysis
were node positivity (P < 0.001), lack of both receptors being
positive (P < 0.001), tumor grade (P < 0.001), HER-2
expression/amplification (P < 0.001), tumor size (P = 0.001),
endocrine treatment (P = 0.002), and vascular invasion (P =
0.02). The results from the final multivariate Cox regression
model are presented in Table 3. Increasing tumor grade resulted
in an increased risk of relapse. Risk of relapse by combined
receptor status ranked as follows: ER/PgR+ > ER+/PgR–
> ER+/PgR unknown > ER+/PgR+. Patients with vascular
invasion had a greater risk of relapse than those without; tumor
with no assessable vascular invasion had an intermediate risk.
Risk of relapse was greatest for patients with a high number of
involved nodes, those with larger tumors, and those with HER-2
overexpressed/amplified tumors. There were no major
violations of the proportional hazards assumption.
Letrozole resulted in a significant reduction in early relapse,
even after adjusting for significant prognostic factors. Figure 1
shows average semiannual hazards of early relapse by treatment.
Table 1. Sites of early relapse by treatment
Site of early relapse Treatment
Letrozole (N = 3863) Tamoxifen (N = 3844)
N % N %
Local 12 0.3 23 0.6
Contralateral breast 11 0.3 15 0.4
Regional 7 0.2 5 0.1
Distant 87 2.3 125 3.3
Soft tissue 3 <0.1 7 0.2
Bone 39 1.0 57 1.5
Viscera 45 1.2 61 1.6
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The difference in hazards appears to emerge around 1 year
following randomization.
Figure 2 shows Cox model hazard ratios and confidence
intervals (CIs) within subgroups of the significant prognostic
factors. For all of the subgroups examined, with the exception of
the grade 3 cohort, fewer early relapses were observed for the
letrozole group compared with the tamoxifen group. The 95%
CI for the hazard ratio of risk of early relapse for letrozole
compared with tamoxifen did not cross the solid vertical line at
1.0 for patients with tumors that were bigger than 2 cm, grade 1
or 2, ER+ and PgR+/unknown, with four or more positive
nodes, and with vascular invasion.
Within each subgroup in Figure 2, boxes located to the left of
the dashed vertical line indicate that the observed effect of
letrozole in that subgroup was greater than the effect of letrozole
in the overall population. Though the observed effect of
letrozole was greatest in patients with tumors that were grade 1,
ER+/PgR unknown, or HER-2 over-expressing/amplified, these
results were on the basis of little data (small boxes for hazard
ratios and wide CIs). The data indicating a larger benefit from
letrozole were statistically more robust for patients with four or
more positive nodes, those with tumors >2 cm in diameter, or
those with vascular invasion.
A comparison of the hazard ratios across the subgroup levels
of each covariate (e.g. between tumors £2 cm and >2 cm) in
Figure 2 shows that none of the prognostic factors is
significantly predictive for the specific efficacy of letrozole. None
of the interaction terms was statistically significant, as seen by
the fact that, for each covariate, the CIs across levels of that
covariate overlap. For example, the benefit of letrozole in
patients with four or more positive nodes did not significantly
differ from the benefit seen in patients with one to three or zero
positive nodes.
Thus, the results of this multivariate analysis show that (i)
letrozole significantly reduced the risk of early relapse compared
with tamoxifen overall; (ii) within many but not all subgroups
letrozole was significantly better than tamoxifen in preventing
early relapse; and (iii) statistically there was no difference in the
effect of letrozole across subgroup levels of any of the covariates
examined, but letrozole was qualitatively more effective than
tamoxifen within some subgroups (patients with four or more
positive nodes, tumors > 2cm, or with vascular invasion).
discussion
Though a number of trials have shown superiority of aromatase
inhibitors compared with standard tamoxifen therapy or
placebo, it remains unclear whether an aromatase inhibitor
should be given in sequence with tamoxifen or in place of it. Use
of mathematical models with data from the aforementioned
aromatase inhibitor trials led Cuzick et al. [6] to assert that early
treatment with an aromatase inhibitor is superior to sequencing
after 2 years of tamoxifen. Punglia et al. [7] reached the opposite
conclusion when applying simulations on the basis of data from
the aforementioned trials, namely that sequential therapy is
preferable to an aromatase inhibitor alone.
Treatment choices on the basis of prognostic factors of
relapse, without focusing on early relapses, have been previously
studied. Among patients with small tumors without axillary
Table 2. Covariates according to whether or not an early relapse occurred
Early relapse
No (N = 7422) Yes (N = 285)
N % N %
Treatment
Letrozole 3746 97.0 117 3.0
Tamoxifen 3676 95.6 168 4.4
Age at randomization
<55 years 1399 96.3 53 3.7
55–64 years 3392 96.5 124 3.5
‡65 years 2631 96.1 108 3.9
Tumor size
£2cm 4711 97.8 108 2.2
>2cm 2711 93.9 177 6.1
Tumor grade
Grade 1 2015 98.2 36 1.8
Grade 2 3650 96.6 127 3.4
Grade 3 1092 92.8 85 7.2
Missing 665 94.7 37 5.3
Mitotic grade
Grade 0 3 100.0 0 0.0
Grade 1 3297 97.8 74 2.2
Grade 2 1616 95.8 71 4.2
Grade 3 695 92.2 59 7.8
Missing 1811 95.7 81 4.3
ER/PgR receptor status
ER+/PgR+ 4762 97.5 122 2.5
ER+/PgR 1498 94.5 87 5.5
ER+/PgR unknown 1039 94.2 64 5.8
ER/PgR+ 123 91.1 12 8.9
HER-2 expression
Normal 3865 97.5 101 2.5
Overexpressed 239 90.2 26 9.8
Missing 3318 95.5 158 4.5
Axillary node positivity
0 positive 4411 98.2 81 1.8
1–3 positive 2157 96.4 81 3.6
‡4 positive 854 87.4 123 12.6
Vascular invasion
No 5605 97.2 161 2.8
Yes 1247 92.7 98 7.3
Not assessable 419 96.1 17 3.9
Missing 151 94.4 9 5.6
Radiotherapy given
No 2059 95.7 93 4.3
Yes 5355 96.5 192 3.5
Missing 8 100.0 0 0.0
Primary surgery
Breast-conserving procedure 4303 98.1 84 1.9
Mastectomy 3114 93.9 201 6.1
Other 5 100.0 0 0.0
Chemotherapy use
None 5564 96.7 192 3.3
Adjuvant only 1723 95.6 79 4.4
Neo-adjuvant with/without
adjuvant
134 90.5 14 9.5
Missing 1 100.0 0 0.0
ER, estrogen receptor; PgR, progesterone receptor.
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nodal involvement, and who did not receive adjuvant systemic
therapy, high grade and lymphovascular invasion are commonly
considered prognostic factors for recurrence at 10 years of
follow-up [8]. Data are somewhat conflicting regarding the
prognostic value of steroid hormone receptor status. According
to a retrospective study by Bardou et al. [9] in the absence of
adjuvant tamoxifen, PgR negativity is not a poor prognostic
factor. In patients treated with tamoxifen, ER+/PgR tumors
displayed more aggressive features compared with ER+/PgR+
tumors [9, 10]. However, in a retrospective study from two
randomized trials of adjuvant tamoxifen versus no other
treatment, Dowsett et al. [11] found that antiestrogen improves
relapse-free survival in case of ER+ tumors, regardless of PgR
status. Nevertheless, these results would be better analyzed
taking into account expression level of PgR [12].
In patients treated with anastrozole in the ATAC trial,
Dowsett et al. [13] found that those with ER+/PgR tumors had
the same prognosis as those with ER+/PgR+ tumors, and that
anastrozole was more effective than tamoxifen in both groups.
Analyses of early relapses are infrequently carried out, but can be
used to inform treatment choices, particularly for high-risk
patients. Our analysis showed that highest risk for early relapse
is linked to tumor burden (tumor size, nodal involvement) and
tumor aggressiveness (high grade, partial endocrine
insensitivity, HER-2neu overexpression, vascular invasion).
These findings are supported by three recent retrospective
analyses carried out on patients treated with tamoxifen [14–16]
or toremifene [16]. These studies identified grade 3 [14, 15],
Table 3. Final multivariate Cox model results
Variable Comparison Hazard ratio 95% CI lower limit 95% CI upper limit P value
Treatment Letrozole versus tamoxifen 0.69 0.5 0.9 0.002
Tumor size >2 versus £2 cm 1.54 1.2 2.0 0.001
Tumor grade Grade 3 versus 1 2.43 1.6 3.6 <0.001
Grade 2 versus 1 1.55 1.1 2.3 0.02
Grade 3 versus 2 1.57 1.2 2.1 0.002
Grade missing versus 1 1.96 1.2 3.1 0.005
ER/PgR status ER+/PgR versus ER+/PgR+ 2.04 1.5 2.7 <0.001
ER+/PgR unknown versus ER+/PgR+ 1.59 1.1 2.2 0.005
ER+/PgR versus ER+/PgR unknown 1.28 0.9 1.8 0.16
ER/PgR+ versus ER+/PgR+ 3.10 1.7 5.6 <0.001
ER/PgR+ versus ER+/PgR 1.52 0.8 2.8 0.17
ER/PgR+ versus ER+/PgR unknown 1.95 1.0 3.7 0.04
HER-2 Overexpressed versus normal 2.48 1.6 3.8 <0.001
Missing versus normal 0.79 0.5 1.2 0.29
Node positivity ‡4 versus 0 positive 4.81 3.5 6.6 <0.001
1–3 versus 0 positive 1.73 1.3 2.4 <0.001
‡4 versus 1–3 positive 2.79 2.1 3.7 <0.001
Vascular invasion Yes versus no 1.39 1.1 1.8 0.02
Not assessable versus no 1.26 0.8 1.9 0.29





















Figure 1. Semiannualized hazards of early relapse by treatment. Tamoxifen
is represented in black by circles; letrozole is represented by gray triangles.
Overall (7707)
Tumor ≤ 2 cm (4711)
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Figure 2. Cox model results for subgroup analyses of time to early relapse.
Results were adjusted by all covariates present in the final multivariate
model. Boxes represent hazard ratios (letrozole : tamoxifen) and lines
represent 95% confidence intervals. Values <1.0 favor letrozole. The size of
the boxes is inversely proportional to the standard error of the hazard
ratio. The dashed vertical line at 0.69 gives the overall hazard ratio estimate
for endocrine treatment in the final multivariate Cox model.
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lymph node involvement [14, 15], and low-positive ER status
[14] as independent significant predictors of early relapse.
Lymphovascular invasion, which was recognized as a poor
prognostic factor in the St Gallen consensus conference [17], is
an independent predictor of metastasis, particularly for patients
with no nodal involvement [18, 19].
Even after controlling for predictors of high risk, we found
that letrozole significantly reduced the risk of early relapse
compared with tamoxifen. Despite the lack of significant
interaction between endocrine treatment and the prognostic
factors of early relapse, multivariate analyses indicated that the
beneficial effect of letrozole versus tamoxifen may be
qualitatively greater for patients with poor prognosis (four or
more positive nodes, tumors >2 cm, or with vascular invasion)
than for patients without poor prognosis (i.e. those with
intermediate risk). For patients with intermediate risk of early
relapse (less than four positive nodes, tumors £2 cm, and
without vascular invasion), tamoxifen may be as effective as
letrozole, and therefore sequential therapy may represent a good
option, with toxicity profiles playing a greater role in therapy
choice. Definitive evidence to support or refute this conjecture
must await the results of ongoing randomized trials.
Curiously, letrozole appeared to be more effective than
tamoxifen in patients with grade 1 tumors, though the number
of recurrences in both treatment groups was low and almost
10% of patients did not have tumor grade available for analysis.
Similarly, although HER-2 status was significant in the model,
almost half of the patients did not have HER-2 measured and
thus results and conclusions may change if all patients were
assessed. Analysis of HER-2 as a predictive factor is important,
considering that PgR expression and the HER-2 signaling
pathway are linked [20, 21], and that among patients treated
with adjuvant tamoxifen, ER+/PgR tumors more frequently
express HER-1 and HER-2, which are associated with poorer
prognosis [10]. A similar analysis of early relapse would be
useful once data from the BIG 1-98 second primary analysis on
the role of switching become available.
In conclusion, letrozole resulted in a significant reduction in
early relapse in BIG 1-98, even after adjusting for significant
prognostic factors, which included node positivity, absence of
both receptors being positive, high grade, HER-2
overexpression/amplification, large tumor size, and vascular
invasion. Subgroup analyses of this large controlled randomized
trial indicate that patients with high risk for early relapse may
benefit most from upfront letrozole, while sequential therapy
might be reserved for patients with intermediate risk, in whom
tamoxifen did not differ significantly from letrozole. The second
primary analysis of BIG 1-98, scheduled for 2008, will shed
more light on this key question and will also address which
sequence of tamoxifen and letrozole is best.
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